Brian D Gonzalez1, Brent J Small2, Mallory G Cases1, Noelle L Williams3, Mayer N Fishman4, Paul B Jacobsen1, Heather S L Jim1. 1. Health Outcomes and Behavior Program, Moffitt Cancer Center, Tampa, Florida. 2. School of Aging Studies, University of South Florida, Tampa, Florida. 3. Sidney Kimmel Medical College at Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania. 4. Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, Florida.
Abstract
BACKGROUND: Patients with prostate cancer receiving androgen deprivation therapy (ADT) are at risk of sleep disturbance; however, to the authors' knowledge, the mechanisms by which ADT may affect sleep are not well understood. The current study compared objective and subjective sleep disturbance in ADT recipients and controls and examined whether sleep disturbance in ADT recipients is attributable to the influence of ADT on hot flashes and nocturia. METHODS: Patients with prostate cancer were assessed before or within 1 month after the initiation of ADT as well as 6 months and 12 months later (78 patients). Patients with prostate cancer were treated with prostatectomy only (99 patients) and men with no history of cancer (108 men) were assessed at similar intervals. Participants self-reported their sleep disturbance (Insomnia Severity Index) and interference from hot flashes (Hot Flash Related Daily Interference Scale). One hundred participants also wore actigraphs for 3 days at the 6-month assessment to measure objective sleep disturbance and reported their nocturia frequency. RESULTS: ADT recipients reported worse sleep disturbance, higher rates of clinically significant sleep disturbance, and greater hot flash interference than controls (Ps≤.03). In cross-sectional analyses among those with actigraphy data, ADT recipients had greater objective sleep disturbance and more episodes of nocturia (Ps<.01). Cross-sectional mediation analyses demonstrated that the association between ADT and objectively and subjectively measured sleep disturbance was partly attributable to nocturia and hot flashes (Ps<.05). CONCLUSIONS: The results of the current study suggest that the association between ADT and sleep may be partly explained by nocturia and hot flash interference. Future studies should examine behavioral and pharmacologic interventions to address these symptoms among ADT recipients. Cancer 2018;124:499-506.
BACKGROUND:Patients with prostate cancer receiving androgen deprivation therapy (ADT) are at risk of sleep disturbance; however, to the authors' knowledge, the mechanisms by which ADT may affect sleep are not well understood. The current study compared objective and subjective sleep disturbance in ADT recipients and controls and examined whether sleep disturbance in ADT recipients is attributable to the influence of ADT on hot flashes and nocturia. METHODS:Patients with prostate cancer were assessed before or within 1 month after the initiation of ADT as well as 6 months and 12 months later (78 patients). Patients with prostate cancer were treated with prostatectomy only (99 patients) and men with no history of cancer (108 men) were assessed at similar intervals. Participants self-reported their sleep disturbance (Insomnia Severity Index) and interference from hot flashes (Hot Flash Related Daily Interference Scale). One hundred participants also wore actigraphs for 3 days at the 6-month assessment to measure objective sleep disturbance and reported their nocturia frequency. RESULTS:ADT recipients reported worse sleep disturbance, higher rates of clinically significant sleep disturbance, and greater hot flash interference than controls (Ps≤.03). In cross-sectional analyses among those with actigraphy data, ADT recipients had greater objective sleep disturbance and more episodes of nocturia (Ps<.01). Cross-sectional mediation analyses demonstrated that the association between ADT and objectively and subjectively measured sleep disturbance was partly attributable to nocturia and hot flashes (Ps<.05). CONCLUSIONS: The results of the current study suggest that the association between ADT and sleep may be partly explained by nocturia and hot flash interference. Future studies should examine behavioral and pharmacologic interventions to address these symptoms among ADT recipients. Cancer 2018;124:499-506.
Authors: Janet S Carpenter; Julie L Elam; Sheila H Ridner; Pam H Carney; Gloria J Cherry; Heather L Cucullu Journal: Oncol Nurs Forum Date: 2004-05 Impact factor: 2.172
Authors: Ashley M Nelson; Brian D Gonzalez; Heather S L Jim; Julie M Cessna; Steven K Sutton; Brent J Small; Mayer N Fishman; Babu Zachariah; Paul B Jacobsen Journal: Support Care Cancer Date: 2016-05-03 Impact factor: 3.603
Authors: Kathryn T Dinh; Gally Reznor; Vinayak Muralidhar; Brandon A Mahal; Michelle D Nezolosky; Toni K Choueiri; Karen E Hoffman; Jim C Hu; Christopher J Sweeney; Quoc-Dien Trinh; Paul L Nguyen Journal: J Clin Oncol Date: 2016-04-11 Impact factor: 50.717
Authors: Nikolaos Papachristou; Payam Barnaghi; Bruce Cooper; Kord M Kober; Roma Maguire; Steven M Paul; Marilyn Hammer; Fay Wright; Jo Armes; Eileen P Furlong; Lisa McCann; Yvette P Conley; Elisabeth Patiraki; Stylianos Katsaragakis; Jon D Levine; Christine Miaskowski Journal: Sci Rep Date: 2019-02-19 Impact factor: 4.379
Authors: Sheila N Garland; Josée Savard; Sarah L Eisel; Richard J Wassersug; Nicholas J Rockwood; John Thoms; Heather S L Jim; Brian D Gonzalez Journal: Cancer Date: 2021-08-19 Impact factor: 6.860
Authors: Shalini Mondal; Steve Edwards; Erik Wibowo; Hashim Ahmed; Richard J Wassersug; Jason Ellis; Maximus Isaac; Dagmara Dimitriou; Stephen Mangar Journal: Healthcare (Basel) Date: 2022-04-30
Authors: Jamie S Myers; Catherine Siengsukon; Joseph Sherman; Xinglei Shen; Lauren T Ptomey; Robert Montgomery; Karen Bock; Anna Rice; William P Parker; Sally Maliski Journal: Cancer Nurs Date: 2022-04-20 Impact factor: 2.760